N-of-1: When You Become the Study

Posted on Tuesday February 24, 2026 in Naked Heart

For busy people, or to tune in when on the move, Google Notebook AI audio podcast are available for this story beneath.

Why some of the most useful experiments in medicine start with a single person

Modern medicine is built on averages.

Large randomised trials tell us what tends to work for most people, most of the time. That approach has transformed outcomes in acute disease and population health. But it has an important limitation: it struggles when biology is heterogeneous, symptoms are subjective, and responses vary widely between individuals.

Because you are not an average.

Anyone who works in clinic sees this daily. Two patients with the same diagnosis, similar investigations, and identical treatments can have very different outcomes. One improves. The other does not. Guidelines offer little explanation. The biology underneath is clearly individual.

This is the gap that N-of-1 medicine was designed to address.(1–4)

What does “N-of-1” actually mean?

In research, N refers to the number of participants in a study.

An N-of-1 trial simply means the number is one.

Instead of asking “What works on average?”, the question becomes:

“What happens in this individual when a specific variable is deliberately changed and the response is carefully observed?”

This is not a fringe idea. N-of-1 trials have been formally described in the medical literature for decades as a rigorous method for individualising treatment when population evidence is limited, responses are variable, or outcomes are subjective but important.(1–4)

In fact, N-of-1 trials were originally proposed as a way to bring scientific discipline into everyday clinical decision-making for individual patients.(1)

Why N-of-1 thinking matters now

There are many areas of modern medicine where the evidence base is incomplete — not because science has failed, but because large trials are slow, expensive, and necessarily conservative.

Meanwhile, clinicians and patients repeatedly observe patterns that do not yet have definitive trial support. Symptoms improve when certain behaviours change. Other interventions fail despite theoretical promise. These observations are often dismissed as “anecdotal”.

But a well-designed N-of-1 trial is not anecdote. It is structured self-experimention, carried out with the same principles that underpin clinical research: baseline measurement, controlled change, and careful observation.(2,5)

This approach is particularly relevant when:

responses to treatment vary widely
outcomes are experiential (e.g. symptoms, function, quality of life)
interventions are low risk
the individual is motivated to engage

These are exactly the situations where population averages are least helpful — and where N-of-1 methods are most informative.(2,3)

A worked example: seeing what averages hide

In a previous blog (“If you spend 2 minutes brushing your teeth, why not 10 minutes saving your life?”), I shared a longitudinal chart from a single patient tracking weight, waist circumference, and visceral adipose tissue over time.

That figure is a useful illustration of N-of-1 thinking — not because it proves a universal truth, but because it shows how divergent biological signals emerge in individuals.

Weight plateaued. Waist and visceral fat continued to fall. Metabolic health improved despite minimal change on the scale.

That pattern would be diluted or lost entirely in a population mean. But for the individual, it was decisive. It informed motivation, guided further intervention, and prevented the common mistake of abandoning an effective strategy because the “wrong” metric had stalled.

This is precisely the kind of insight N-of-1 methodology was designed to deliver.(1,5)

From compliance to curiosity

There is another, often overlooked, reason N-of-1 approaches work: psychology.

Many health interventions fail not because people lack information, but because sustained behaviour change is biologically and psychologically resisted. Fear-based messaging and abstract risk reduction are weak motivators.

N-of-1 trials change the frame.

The patient is no longer being told what to do. They are testing a hypothesis about their own body. Behaviour becomes an experiment. Outcomes become feedback. Curiosity replaces compliance.

This shift — from passive recipient to active investigator — is a recognised strength of N-of-1 designs and one of the reasons they are increasingly discussed in the context of personalised medicine.(3,5)

What the N-of-1 series is — and what it isn’t

The articles tagged n-of-1 are not treatment guidelines, and they are not claims of universal benefit. They do not replace medication where medication is clearly indicated.

What they do is:

set out a plausible hypothesis
summarise what evidence exists and where it is incomplete
explain why the idea may be reasonable to test safely
and encourage individuals to observe their own response honestly

This is entirely consistent with the original intent of N-of-1 methodology: improving care for individuals when certainty is elusive and averages are insufficient.(1,2,4)

An invitation, not an instruction

You do not need to agree with every hypothesis.

You do not need to run every experiment.

You do not need to change anything.

But if an article makes you think, “I wonder what would happen if I tested this — just for me”, then it has done its job.

Because the most important study you will ever run

is the one where the subject is you.

N-of-1 Companion: Tracking What Matters

If you’re considering running your own N-of-1 experiment, it helps to have a simple, consistent way to record what changes over time. As a companion to The VAT Trap series, I’ve created a 12-month metabolic diary designed to track the measures that matter most in real life — waist circumference, weight, strength, activity, and symptoms — rather than relying on the weight scale alone.

The diary is intended as a practical tool for people who want to use themselves as the control, identify meaningful trends, and make sense of gradual biological change over months rather than weeks. 🔗 https://amzn.eu/d/0hBEpKDU

References

Guyatt G, Sackett D, Taylor DW, Ghong J, Roberts R, Pugsley S. Determining Optimal Therapy — Randomized Trials in Individual Patients. N Engl J Med [Internet]. 1986 Apr 3 [cited 2026 Feb 4];314(14):889–92. Available from: https://www.nejm.org/doi/full/10.1056/NEJM198604033141406
Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What Ever Happened to N-of-1 Trials? Insiders’ Perspectives and a Look to the Future. Milbank Q [Internet]. 2008 Dec [cited 2026 Feb 4];86(4):533–55. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2690377/
Nikles CJ, Glasziou PP, Del Mar CB, Duggan CM, Mitchell G. N of 1 trials. Practical tools for medication management. Aust Fam Physician. 2000 Nov;29(11):1108–12.
Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. 2015 May 14 [cited 2026 Feb 4]; Available from: https://www.bmj.com/content/350/bmj.h1793
Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Pers Med. 2011 Mar;8(2):161–73.

Bempedoic acid to lower LDL Cholesterol

Bempedoic acid offers a new avenue for patients who require an alternative to statins for managing high cholesterol. Its liver-specific action and excellent safety and side effect profile make it a valuable addition to available treatments we can use to combat high LDL cholesterol levels to reduce coronary inflammation and stabilise high risk coronary plaque.

The SCVC Blog

Cardiovascular care news and articles from our expert team